Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 148 | 31,647 | 48% |
| 2020 | 151 | 35,751 | 50% |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 21% of the cases CMS names in California; 135 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 1,332 | 456,139+1.4%/yr | +1.4%/yr | 129.72.0× | 57% | 501,600 in 2030+1.6%/yr |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
| 2024 |
| 86,283 |
| 56% |
| 2025 est. | ≈ 83,400 | – |
| 2026 est. | ≈ 92,000 | – |
| 2021 |
| 157 |
| 34,545 |
| 52% |
| 2022 | 174 | 44,098 | 53% |
| 2023 | 240 | 60,942 | 55% |
| 2024 | 313 | 86,283 | 56% |
| 2025 from claims | – | 83,446 76,580–88,286 | 56% |
| 2026 forecast | – | 92,010 80,954–106,175 | 56% |
| 2027 forecast | – | 101,203 86,518–120,604 | 56% |
| 2028 forecast | – | 111,313 92,880–136,300 | 56% |
| 2029 forecast | – | 122,430 99,997–153,539 | 57% |
| 2030 forecast | – | 134,655 107,877–172,559 | 57% |
In 2025, 1% inpatient hospital, 15% hospital outpatient, 0% surgery center, 83% office. The share outside the hospital has moved +24 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~92,000 | ~1,200 | ~12,800 | ~77,800 |
| 2027 · ~101,200 | ~1,400 | ~13,300 | ~86,400 |
| 2028 · ~111,300 | ~1,500 | ~14,200 | ~95,400 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 86% (83% in 2025), hospital outpatient about 13% (15% in 2025).
| +43%/yr |
| 26.2 |
| 72% |
| 17,600 in 2030+5.9%/yr |
| Washington | 21 | 7,289+5.2%/yr | +5.2%/yr | 5.9 | 78% | 11,800 in 2030+8.4%/yr |
| Colorado | 27 | 6,374+23%/yr | +23%/yr | 7.8 | 82% | 11,000 in 2030+9.5%/yr |
| Utah | 18 | 5,940+21%/yr | +21%/yr | 16.2 | 77% | 5,190 in 2030−2.2%/yr |
| Oregon | 20 | 3,597+11%/yr | +11%/yr | 5.0 | 89% | 4,970 in 2030+5.5%/yr |
| Idaho | 11 | 2,190+7.1%/yr | +7.1%/yr | 6.8 | 51% | 4,080 in 2030+11%/yr |
| New Mexico | 9 | 2,075+17%/yr | +17%/yr | 5.6 | 92% | 2,610 in 2030+3.9%/yr |
| Montana | 9 | 1,642+11%/yr | +11%/yr | 6.7 | 62% | 1,670 in 2030+0.3%/yr |
| Hawaii | 3 | 546+7.6%/yr | +7.6%/yr | 2.4 | 74% | 1,080 in 2030+12%/yr |
| Wyoming | 0 | 397+25%/yr | +25%/yr | 3.2 | 90% | 650 in 2030+8.5%/yr |
| Alaska | 1 | 290−8.4%/yr | −8.4%/yr | 2.4 | 29% | 500 in 2030+9.7%/yr |
| 57 |
| 2,787−2.3%/yr |
| −2.3%/yr |
| 0.81.0× |
| 2% |
| 3,030 in 2030+1.4%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Organogenesis leads with 23% of company spending on these surgeons in 2025, level with 2024.
In 2025, 31 companies reported engagement with California’s surgeons worth $1.2M in consulting, speaking, meals and travel tied to these products, about $3,716 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.